Group A Streptococcus

Clinical trial results of StreptAvax presented at international vaccine conference

Published in Vaccine Weekly, June 12th, 2002

ID Biomedical announced that Shelly McNeil of Dalhousie University in Halifax presented phase I clinical trial results for StreptAvax at the Fifth Annual Conference on Vaccine Research. McNeil's presentation described the first study in humans of StreptAvax, ID Biomedical's multivalent recombinant vaccine developed to prevent group A streptococcus infections.

The National Foundation for Infectious Diseases (NFID), a sponsor of the conference, issued a press release highlighting the clinical trial results of StreptAvax. The StreptAvax presentation was chosen by NFID because it "represents cutting edge development in the field, and holds great promise for improving...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-06-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry